Kahn Brothers (Trades, Portfolio) manages a $592 million equity portfolio composed of 47 stocks as of the quarter's end. The firm sold shares of the following stocks during the second quarter of 2020.
Merck & Co.
The fund trimmed its position in Merck & Co Inc. (MRK) by 10.15%. The trade had an impact of -1.43% on the portfolio.
The company has a market cap of $27.92 billion and an enterprise value of $39.24 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 106.44% and return on assets of 3.71% are outperforming 70% of companies in the travel and leisure industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.14 is below the industry median of 0.42.
The largest guru shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 0.33% of outstanding shares, followed by Steven Romick (Trades, Portfolio)’s FPA Crescent Fund with 0.28% and First Pacific Advisors (Trades, Portfolio) with 0.15%.
Hologic
The fund reduced its Hologic Inc. (HOLX) holding by 69.04%. The portfolio was impacted by -1.18%.
The company operates in the following segments: breast health, diagnostics, surgical and skeletal health. It has a market cap of $18.66 billion and an enterprise value of $21.24 billion.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. The return on equity of 22.74% and return on assets of 7.55% are outperforming 77% of companies in the medical devices and instruments industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.22 is below the industry median of 1.65.
The largest guru shareholder of the company is Larry Robbins (Trades, Portfolio)’ Glenview Capital with 1.51% of outstanding shares, followed by the Vanguard Health Care Fund (Trades, Portfolio) with 0.71% and Pioneer Investments (Trades, Portfolio) with 0.68%.
GlaxoSmithKline
The fund curbed its position in GlaxoSmithKline PLC (GSK) by 1.66%. The portfolio was impacted by -0.18%.
The pharmaceutical company has a market cap of $103.46 billion and an enterprise value of $142.68 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 62.45% and return on assets of 8.44% are outperforming 79% of companies in the drug manufacturers industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.26 is below the industry median of 0.87.
Some notable guru shareholders are Dodge & Cox with 1.76% of outstanding shares, Jim Simons (Trades, Portfolio)’ Renaissance Technologies with 0.92% and Ken Fisher (Trades, Portfolio) with 0.62%.
MBIA
The fund reduced its position in MBIA Inc. (MBI) by 2.35%, impacting the portfolio by -0.17%.
The financial guaranty insurance provider has a market cap of $541.60 million and an enterprise value of $4.42 billion.
GuruFocus gives the company a profitability and growth rating of 3 out of 10. The return on equity of -73.8% and return on assets of -8.67% are underperforming 99% of companies in the insurance industry. Its financial strength is rated 2 out of 10. The cash-debt ratio of 0.05 is below the industry median of 2.28.
The largest guru shareholder of the company is Kahn Brothers (Trades, Portfolio) with 7.36% of outstanding shares, followed by Simons’ firm with 1.16% and Francis Chou (Trades, Portfolio) with 0.96%.
Seaboard
The investment fund curbed its holding in Seaboard Corp. (SEB) by 2.05%. The trade had an impact of -0.13% on the portfolio.
The company has a market cap of $3.15 billion and an enterprise value of $3.36 billion.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. The return on equity of 1.14% and return on assets of 0.65% are underperforming 59% of companies in the conglomerates industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 0.86 is above the industry median of 0.42.
Other notable guru shareholders include Simons’ firm with 0.6% of outstanding shares, Diamond Hill Capital (Trades, Portfolio) with 0.24% and Third Avenue Management (Trades, Portfolio) with 0.15%.
New York Community Bancorp
The investment fund cut its New York Community Bancorp Inc. (NYCB) position by 1.37%. The trade had an impact of -0.12% on the portfolio.
The multi-bank holding company has a market cap of $4.64 billion and an enterprise value of $18.23 billion.
GuruFocus gives the company a profitability and growth rating of 3 out of 10. The return on equity of 5.53% and return on assets of 0.76% are underperforming 70% of companies in the banks industry. Its financial strength is rated 2 out of 10. The cash-debt ratio of 0.09 is below the industry median of 1.34.
The largest guru shareholder of the company is Barrow, Hanley, Mewhinney & Strauss with 12.23% of outstanding shares, followed by Simons’ firm with 0.42% and Chuck Royce (Trades, Portfolio) with 0.04%.
Bristol-Myers
The investment fund cut its holding of Bristol-Myers Squibb Company (BMY) by 1.01%. The trade had an impact of -0.11% on the portfolio.
The company, which provides drugs for cardiovascular, oncology and immune disorders, has a market cap of $134.56 billion and an enterprise value of $163.84 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 3.17% and return on assets of 1.17% are underperforming 50% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10 with a cash-debt ratio of 0.39.
The largest guru shareholder of the company is Simons’ firm with 2.92% of outstanding shares, followed by Dodge & Cox with 1.60% and the Vanguard Health Care Fund (Trades, Portfolio) with 1.55%.
Disclosure: I do not own any stocks mentioned.
Read more here:
- Hillman Capital Exits Raytheon, Cuts Amazon
- Markel Gayner Exits CarMax, Marriott International
- Pzena Investment Cuts Amgen, Halliburton
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
